<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00808808</url>
  </required_header>
  <id_info>
    <org_study_id>MI-MA-181</org_study_id>
    <nct_id>NCT00808808</nct_id>
  </id_info>
  <brief_title>Assessing Choice in the Employer Setting (ACES) Study</brief_title>
  <acronym>MA181</acronym>
  <official_title>Assessing Choice in the Employer Setting (ACES Study): An Observational Study to Assess the Impact of Offering Intranasal Vaccine on Influenza Vaccination Rates in the Employer Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Passport Health</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine, among adults and in the total population, the
      effects of offering a choice of FluMist or trivalent inactivated vaccine (TIV) in the
      employer setting when compared to a control group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to determine, among adults in the 18-49 year old population and in
      the total population, the effects of offering a choice of FluMist or TIV with and without
      enhanced advertisement/added incentive on the overall influenza vaccination rates in the
      employer setting when compared to a control group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Vaccination Rate, All Ages</measure>
    <time_frame>30Sep2008 through 23Dec2008</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Vaccination Rate, Employees 18 to 49 Years of Age</measure>
    <time_frame>30Sep2008 through 23Dec2008</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Influenza Vaccination Rate From Baseline Season to Intervention Season in the Total Population</measure>
    <time_frame>2007-2008 season through 2008-2009 season</time_frame>
    <description>Rate difference by arm from baseline to intervention season</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Influenza Vaccination Rate From Baseline Season to Intervention Season in Employees 18-49 Years of Age</measure>
    <time_frame>2007-2008 season through 2008-2009 season</time_frame>
    <description>Rate difference by arm from baseline to intervention season</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Eligible Participants 18-49 Years of Age Choosing FluMist During Intervention Season</measure>
    <time_frame>30Sep2008 through 23Dec2008</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of Participants 18-49 Years of Age Choosing FluMist vs TIV: Race</measure>
    <time_frame>30Sep2008 through 23Dec2008</time_frame>
    <description>Percent of participants 18-49 years of age who chose FluMist vs TIV for influenza vaccination and who self-identified as white</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of Participants 18-49 Years of Age Choosing FluMist vs TIV: Education</measure>
    <time_frame>30Sep2008 through 23Dec2008</time_frame>
    <description>Percent of participants 18-49 years of age who chose FluMist vs TIV for influenza vaccination and who self-identified as college graduates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of Participants 18-49 Years of Age Choosing FluMist vs TIV: Gender</measure>
    <time_frame>30Sep2008 through 23Dec2008</time_frame>
    <description>Percent of participants 18-49 years of age who chose FluMist vs TIV for influenza vaccination and who self-identified as male.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">4411</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Arm A (Control)</arm_group_label>
    <description>A control arm of usual care offering TIV with baseline advertisement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Choice)</arm_group_label>
    <description>An intervention arm offering choice of TIV or FluMist with baseline advertisement, including advertisement to highlight the availability of FluMist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (Choice Plus)</arm_group_label>
    <description>An intervention arm offering choice of TIV or FluMist with enhanced advertisement and additional incentives for receiving an influenza vaccination</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Choice of TIV or FluMist with baseline advertisement</intervention_name>
    <description>An intervention arm offering choice of TIV or FluMist with baseline advertisement, including advertisement to highlight the availability of FluMist</description>
    <arm_group_label>Arm B (Choice)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Choice of TIV or FluMist with enhanced advertisement and incentives</intervention_name>
    <description>An intervention arm offering choice of TIV or FluMist with enhanced advertisement and additional incentives for receiving an influenza vaccination</description>
    <arm_group_label>Arm C (Choice Plus)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Control - Usual care offering TIV only with baseline advertisement</intervention_name>
    <description>A control arm of usual care offering TIV with baseline advertisement</description>
    <arm_group_label>Arm A (Control)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults at least 18 years of age who are current employees attending the influenza clinic
        sponsored by their employer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for employer sites:

          -  Located in the United States

          -  Has not previously offered FluMist in an employee vaccination program in the past or
             FluMist represented less than 5% of all vaccine received at past programs

          -  Data are available that will allow for a reliable estimate of the employee (total and
             18-49 year old populations) vaccination rate for the 2007-2008 influenza season
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seth Toback, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chatsworth</city>
        <state>California</state>
        <zip>91311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novato</city>
        <state>California</state>
        <zip>94945</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95833</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>96050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sunnyvale</city>
        <state>California</state>
        <zip>94089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91362</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33619</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hebron</city>
        <state>Kentucky</state>
        <zip>41048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>LaGrange</city>
        <state>Kentucky</state>
        <zip>40031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lawrenceburg</city>
        <state>Kentucky</state>
        <zip>40342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calverton</city>
        <state>Maryland</state>
        <zip>20705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cockeysville</city>
        <state>Maryland</state>
        <zip>21030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Crofton</city>
        <state>Maryland</state>
        <zip>21114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hanover</city>
        <state>Maryland</state>
        <zip>21076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hunt Valley</city>
        <state>Maryland</state>
        <zip>21031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Laurel</city>
        <state>Maryland</state>
        <zip>20707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sparks</city>
        <state>Maryland</state>
        <zip>21152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Larwenceville</city>
        <state>New Jersey</state>
        <zip>8648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14586</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14625</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ohio</state>
        <zip>45015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lebanon</city>
        <state>Ohio</state>
        <zip>45036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Chester</city>
        <state>Ohio</state>
        <zip>45096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fredericksburg</city>
        <state>Virginia</state>
        <zip>22401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <results_reference>
    <citation>Lin CJ, Nowalk MP, Toback SL, Rousculp MD, Raymund M, Ambrose CS, Zimmerman RK. Importance of vaccination habit and vaccine choice on influenza vaccination among healthy working adults. Vaccine. 2010 Nov 10;28(48):7706-12. doi: 10.1016/j.vaccine.2010.07.009. Epub 2010 Jul 16.</citation>
    <PMID>20638452</PMID>
  </results_reference>
  <results_reference>
    <citation>Nowalk MP, Lin CJ, Toback SL, Rousculp MD, Eby C, Raymund M, Zimmerman RK. Improving influenza vaccination rates in the workplace: a randomized trial. Am J Prev Med. 2010 Mar;38(3):237-46. doi: 10.1016/j.amepre.2009.11.011. Epub 2009 Dec 24.</citation>
    <PMID>20036102</PMID>
  </results_reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2008</study_first_submitted>
  <study_first_submitted_qc>December 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2008</study_first_posted>
  <results_first_submitted>July 30, 2012</results_first_submitted>
  <results_first_submitted_qc>August 10, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 13, 2012</results_first_posted>
  <last_update_submitted>October 28, 2013</last_update_submitted>
  <last_update_submitted_qc>October 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2013</last_update_posted>
  <responsible_party>
    <name_title>Seth Toback, MD</name_title>
    <organization>Medimmune LLC</organization>
  </responsible_party>
  <keyword>FluMist, TIV, vaccination rates</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Potential employers estimated to have at least 60 employees were contacted to determine their interest in participating in the study and were offered an influenza vaccine clinic on site at no cost. A screening questionnaire to determine eligibility was completed. Sites were excluded according to the study inclusion and exclusion criteria.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A (Control)</title>
          <description>A control arm of usual care offering TIV with baseline advertisement</description>
        </group>
        <group group_id="P2">
          <title>Arm B (Choice)</title>
          <description>An intervention arm offering choice of TIV or FluMist with baseline advertisement, including advertisement to highlight the availability of FluMist</description>
        </group>
        <group group_id="P3">
          <title>Arm C (Choice Plus)</title>
          <description>An intervention arm offering choice of TIV or FluMist with enhanced advertisement and additional incentives for receiving an influenza vaccination</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4078">Started includes all employees at participating sites.</participants>
                <participants group_id="P2" count="3757">Started includes all employees at participating sites</participants>
                <participants group_id="P3" count="4387">Started includes all employees at participating sites.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="1392">Vaccinated includes all employees who were vaccinated at the employee vaccination clinics.</participants>
                <participants group_id="P2" count="1489">Vaccinated includes all employees who were vaccinated at the employee vaccination clinics.</participants>
                <participants group_id="P3" count="2132">Vaccinated includes all employees who were vaccinated at the employee vaccination clinics.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1261">Completed includes vaccinated employees who completed surveys.</participants>
                <participants group_id="P2" count="1320">Completed includes vaccinated employees who completed surveys.</participants>
                <participants group_id="P3" count="1830">Completed includes vaccinated employees who completed surveys.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2817"/>
                <participants group_id="P2" count="2437"/>
                <participants group_id="P3" count="2557"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Vaccinated; survey not completed</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="169"/>
                <participants group_id="P3" count="302"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Employee was not vaccinated.</title>
              <participants_list>
                <participants group_id="P1" count="2686"/>
                <participants group_id="P2" count="2268"/>
                <participants group_id="P3" count="2255"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A (Control)</title>
          <description>A control arm of usual care offering TIV with baseline advertisement</description>
        </group>
        <group group_id="B2">
          <title>Arm B (Choice)</title>
          <description>An intervention arm offering choice of TIV or FluMist with baseline advertisement, including advertisement to highlight the availability of FluMist</description>
        </group>
        <group group_id="B3">
          <title>Arm C (Choice Plus)</title>
          <description>An intervention arm offering choice of TIV or FluMist with enhanced advertisement and additional incentives for receiving an influenza vaccination</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1392"/>
            <count group_id="B2" value="1489"/>
            <count group_id="B3" value="2132"/>
            <count group_id="B4" value="5013"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 to 49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="983"/>
                    <measurement group_id="B2" value="988"/>
                    <measurement group_id="B3" value="1398"/>
                    <measurement group_id="B4" value="3369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>â‰¥ 50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="409"/>
                    <measurement group_id="B2" value="501"/>
                    <measurement group_id="B3" value="734"/>
                    <measurement group_id="B4" value="1644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <description>Includes all vaccinated employees, not only participants who completed surveys.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="748"/>
                    <measurement group_id="B2" value="814"/>
                    <measurement group_id="B3" value="808"/>
                    <measurement group_id="B4" value="2370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="644"/>
                    <measurement group_id="B2" value="675"/>
                    <measurement group_id="B3" value="1324"/>
                    <measurement group_id="B4" value="2643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Vaccination Rate, All Ages</title>
        <time_frame>30Sep2008 through 23Dec2008</time_frame>
        <population>All employees at participating sites, including those who were vaccinated and those who were not</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Control)</title>
            <description>A control arm of usual care offering TIV with baseline advertisement</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Choice)</title>
            <description>An intervention arm offering choice of TIV or FluMist with baseline advertisement, including advertisement to highlight the availability of FluMist</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Choice Plus)</title>
            <description>An intervention arm offering choice of TIV or FluMist with enhanced advertisement and additional incentives for receiving an influenza vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Vaccination Rate, All Ages</title>
          <population>All employees at participating sites, including those who were vaccinated and those who were not</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4078"/>
                <count group_id="O2" value="3757"/>
                <count group_id="O3" value="4387"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.6"/>
                    <measurement group_id="O2" value="45.1"/>
                    <measurement group_id="O3" value="51.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Vaccination Rate, Employees 18 to 49 Years of Age</title>
        <time_frame>30Sep2008 through 23Dec2008</time_frame>
        <population>All vaccinated employees at participating sites, including those who completed surveys and those who did not</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Control)</title>
            <description>A control arm of usual care offering TIV with baseline advertisement</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Choice)</title>
            <description>An intervention arm offering choice of TIV or FluMist with baseline advertisement, including advertisement to highlight the availability of FluMist</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Choice Plus)</title>
            <description>An intervention arm offering choice of TIV or FluMist with enhanced advertisement and additional incentives for receiving an influenza vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Vaccination Rate, Employees 18 to 49 Years of Age</title>
          <population>All vaccinated employees at participating sites, including those who completed surveys and those who did not</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="983"/>
                <count group_id="O2" value="988"/>
                <count group_id="O3" value="1398"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5"/>
                    <measurement group_id="O2" value="40.9"/>
                    <measurement group_id="O3" value="46.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Influenza Vaccination Rate From Baseline Season to Intervention Season in the Total Population</title>
        <description>Rate difference by arm from baseline to intervention season</description>
        <time_frame>2007-2008 season through 2008-2009 season</time_frame>
        <population>All vaccinated employees at participating sites, including those who completed surveys and those who did not</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Control)</title>
            <description>A control arm of usual care offering TIV with baseline advertisement</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Choice)</title>
            <description>An intervention arm offering choice of TIV or FluMist with baseline advertisement, including advertisement to highlight the availability of FluMist</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Choice Plus)</title>
            <description>An intervention arm offering choice of TIV or FluMist with enhanced advertisement and additional incentives for receiving an influenza vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Influenza Vaccination Rate From Baseline Season to Intervention Season in the Total Population</title>
          <description>Rate difference by arm from baseline to intervention season</description>
          <population>All vaccinated employees at participating sites, including those who completed surveys and those who did not</population>
          <units>percentage points</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1392"/>
                <count group_id="O2" value="1489"/>
                <count group_id="O3" value="2132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="4.8"/>
                    <measurement group_id="O3" value="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Influenza Vaccination Rate From Baseline Season to Intervention Season in Employees 18-49 Years of Age</title>
        <description>Rate difference by arm from baseline to intervention season</description>
        <time_frame>2007-2008 season through 2008-2009 season</time_frame>
        <population>All vaccinated employees 18-49 years of age at participating sites, including those who completed surveys and those who did not</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Control)</title>
            <description>A control arm of usual care offering TIV with baseline advertisement</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Choice)</title>
            <description>An intervention arm offering choice of TIV or FluMist with baseline advertisement, including advertisement to highlight the availability of FluMist</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Choice Plus)</title>
            <description>An intervention arm offering choice of TIV or FluMist with enhanced advertisement and additional incentives for receiving an influenza vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Influenza Vaccination Rate From Baseline Season to Intervention Season in Employees 18-49 Years of Age</title>
          <description>Rate difference by arm from baseline to intervention season</description>
          <population>All vaccinated employees 18-49 years of age at participating sites, including those who completed surveys and those who did not</population>
          <units>percentage points</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="983"/>
                <count group_id="O2" value="988"/>
                <count group_id="O3" value="1398"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7"/>
                    <measurement group_id="O2" value="2.4"/>
                    <measurement group_id="O3" value="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Eligible Participants 18-49 Years of Age Choosing FluMist During Intervention Season</title>
        <time_frame>30Sep2008 through 23Dec2008</time_frame>
        <population>All vaccinated employees 18-49 years of age at participating sites, including those who completed surveys and those who did not</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Control)</title>
            <description>A control arm of usual care offering TIV with baseline advertisement</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Choice)</title>
            <description>An intervention arm offering choice of TIV or FluMist with baseline advertisement, including advertisement to highlight the availability of FluMist</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Choice Plus)</title>
            <description>An intervention arm offering choice of TIV or FluMist with enhanced advertisement and additional incentives for receiving an influenza vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Eligible Participants 18-49 Years of Age Choosing FluMist During Intervention Season</title>
          <population>All vaccinated employees 18-49 years of age at participating sites, including those who completed surveys and those who did not</population>
          <units>percent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="983"/>
                <count group_id="O2" value="988"/>
                <count group_id="O3" value="1398"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="19.1"/>
                    <measurement group_id="O3" value="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characteristics of Participants 18-49 Years of Age Choosing FluMist vs TIV: Race</title>
        <description>Percent of participants 18-49 years of age who chose FluMist vs TIV for influenza vaccination and who self-identified as white</description>
        <time_frame>30Sep2008 through 23Dec2008</time_frame>
        <population>All participants who completed surveys and were eligible to receive FluMist</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccinated With FluMist</title>
            <description>Characteristics of vaccinated employees 18-49 years of age who were eligible for FluMist and chose vaccination with FluMist, and who self-identified as white</description>
          </group>
          <group group_id="O2">
            <title>Vaccinated With TIV</title>
            <description>Characteristics of vaccinated employees 18-49 years of age who were eligible for FluMist and chose vaccination with TIV, and who self-identified as white.</description>
          </group>
        </group_list>
        <measure>
          <title>Characteristics of Participants 18-49 Years of Age Choosing FluMist vs TIV: Race</title>
          <description>Percent of participants 18-49 years of age who chose FluMist vs TIV for influenza vaccination and who self-identified as white</description>
          <population>All participants who completed surveys and were eligible to receive FluMist</population>
          <units>percent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="1990"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.8"/>
                    <measurement group_id="O2" value="71.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characteristics of Participants 18-49 Years of Age Choosing FluMist vs TIV: Education</title>
        <description>Percent of participants 18-49 years of age who chose FluMist vs TIV for influenza vaccination and who self-identified as college graduates.</description>
        <time_frame>30Sep2008 through 23Dec2008</time_frame>
        <population>All participants who completed surveys and were eligible to receive FluMist</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccinated With FluMist</title>
            <description>Characteristics of vaccinated employees 18-49 years of age who were eligible for FluMist and chose vaccination with FluMist, and who self-identified as college graduates.</description>
          </group>
          <group group_id="O2">
            <title>Vaccinated With TIV</title>
            <description>Characteristics of vaccinated employees 18-49 years of age who were eligible for FluMist and chose vaccination with TIV, and who self-identified as college graduates.</description>
          </group>
        </group_list>
        <measure>
          <title>Characteristics of Participants 18-49 Years of Age Choosing FluMist vs TIV: Education</title>
          <description>Percent of participants 18-49 years of age who chose FluMist vs TIV for influenza vaccination and who self-identified as college graduates.</description>
          <population>All participants who completed surveys and were eligible to receive FluMist</population>
          <units>percent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="1990"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.4"/>
                    <measurement group_id="O2" value="52.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characteristics of Participants 18-49 Years of Age Choosing FluMist vs TIV: Gender</title>
        <description>Percent of participants 18-49 years of age who chose FluMist vs TIV for influenza vaccination and who self-identified as male.</description>
        <time_frame>30Sep2008 through 23Dec2008</time_frame>
        <population>All participants who completed surveys and were eligible to receive FluMist</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccinated With FluMist</title>
            <description>Characteristics of vaccinated employees 18-49 years of age who were eligible for FluMist and chose vaccination with FluMist, and who self-identified as male.</description>
          </group>
          <group group_id="O2">
            <title>Vaccinated With TIV</title>
            <description>Characteristics of vaccinated employees 18-49 years of age who were eligible for FluMist and chose vaccination with TIV, and who self-identified as male.</description>
          </group>
        </group_list>
        <measure>
          <title>Characteristics of Participants 18-49 Years of Age Choosing FluMist vs TIV: Gender</title>
          <description>Percent of participants 18-49 years of age who chose FluMist vs TIV for influenza vaccination and who self-identified as male.</description>
          <population>All participants who completed surveys and were eligible to receive FluMist</population>
          <units>percent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
                <count group_id="O2" value="1990"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.9"/>
                    <measurement group_id="O2" value="49.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>September 2008 - December 2008</time_frame>
      <desc>Participants received commercial vaccine per routine care at employer clinics; no investigational treatment was given. Safety data were not collected. Any participant who experienced an adverse event associated with a MedImmune commercial vaccine was to be advised to notify the MedImmune Patient Safety Department. No such events were reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A (Control)</title>
          <description>A control arm of usual care offering TIV with baseline advertisement</description>
        </group>
        <group group_id="E2">
          <title>Arm B (Choice)</title>
          <description>An intervention arm offering choice of TIV or FluMist with baseline advertisement, including advertisement to highlight the availability of FluMist</description>
        </group>
        <group group_id="E3">
          <title>Arm C (Choice Plus)</title>
          <description>An intervention arm offering choice of TIV or FluMist with enhanced advertisement and additional incentives for receiving an influenza vaccination</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.The principal investigators (PIs) also agree for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was conducted during a single season, data to evaluate effects of the intervention by race were unavailable, baseline vaccination data were available at the company level only, and vaccines received outside the workplace were not assessed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Seth Toback, MD</name_or_title>
      <organization>MedImmune, LLC</organization>
      <phone>301-398-0000</phone>
      <email>tobacks@medimmune.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

